Faculty

Back to Index
Eva Astrid Operskalski, PhD
Associate Professor of Research Pediatrics
Pediatrics
HRA 300 1640 Marengo Off Campus Los Angeles
+1 323 865 1554

Overview

Dr. Operskalski is Director of Clinical Research at the MCA Center and has over 25 years experience co-directing or managing complex multi-center investigations of factors that influence HIV and hepatitis B and C disease occurrence and outcome. Since joining MCA she has coordinated the numerous clinical research studies carried out by the program, including studies of the Pediatric AIDS Clinical Trials Group (PACTG), which is now the International Maternal Pediatric Adolescent Center Trials (IMPAACT) Group, other NIH-funded studies, and MCA's own investigator-initiated studies. The studies include therapeutic trials for HIV and other infectious diseases, vaccine studies, and observational studies of long-term outcomes of disease and therapy. She has participated in the development of collaborative activities related to maternal child and adolescent infectious disease prevention and treatment, including successful grant proposals to the national Health Resources and Services Administration to expand MCA’s coordinated clinical services and access to research for women, infants, children, and youth. Dr. Operskalski's research focus has been the epidemiology of HIV, HCV, and other transfusion-transmitted infections; specifically, factors that influence progression from infection to disease (including the effect of interactions of HIV, HTLV, HBV, HCV, EBV, CMV on progression and transmission of each) and factors that influence transmission by blood transfusion, and heterosexual and household contact. She was Principal Investigator for a clinic-based HIV vaccine preparedness (VPS) pilot study, sponsored by the PACTG, to investigate whether network analysis can be used to establish clinic-based cohorts of adolescents for HIV vaccine preparedness activities and vaccine trials. The VPS brought together a multi-disciplinary team of investigators from the KSOM Departments of Pediatrics and Preventive Medicine, as well as from Johns Hopkins University School of Public Health, and the Desmond Tutu HIV Centre in Cape Town and the Perinatal HIV Research Unit in Johannesburg, South Africa. These investigators have extensive experience and expertise in public health, epidemiology, prevention, social network mapping, and clinical research.

Publications

Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr. 2016 Feb 1; 71(2):155-62. View in: PubMed

Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women. J Acquir Immune Defic Syndr. 2016 Feb 1; 71(2):172-80. View in: PubMed

Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion. 2014 Mar; 54(3):672-80. View in: PubMed

Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS. 2013 Jun 1; 27(9):1473-81. View in: PubMed

A comparison of MSM stigma, HIV stigma and depression in HIV-positive Latino and African American men who have sex with men (MSM). AIDS Behav. 2013 May; 17(4):1454-64. View in: PubMed

HHV-8, Transfusion, and Mortality. J Infect Dis. 2012 Nov; 206(10):1485-7. View in: PubMed

The Effect of Prenatal Highly Active Antiretroviral Therapy on the Transmission of Congenital and Perinatal/Early Postnatal Cytomegalovirus Among HIV-Infected and HIV-Exposed Infants. Clin Infect Dis. 2012 Sep; 55(6):877-84. View in: PubMed

Detection of host immune responses in acute phase sera of spontaneous resolution versus persistent hepatitis C virus infection. J Gen Virol. 2012 Aug; 93(Pt 8):1673-9. View in: PubMed

Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr. 2012 May 1; 60(1):99-110. View in: PubMed

Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women? AIDS Behav. Do social support, stress, disclosure and stigma influence retention in HIV care for Latino and African American men who have sex with men and women? AIDS Behav. 2011 Aug; 15(6):1098-110. View in: PubMed

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011 Mar; 8(1):12-22. View in: PubMed

Transfusion transmission of highly prevalent commensal human viruses. Transfusion. 2010 Nov; 50(11):2474-83. View in: PubMed

Social support, stress and social network characteristics among HIV-positive Latino and African American women and men who have sex with men. AIDS Behav. 2010 Oct; 14(5):1149-58. View in: PubMed

Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis. 2010 Mar 15; 201(6):823-34. View in: PubMed

Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr. 2009 Dec 1; 52(4):514-23. View in: PubMed

Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis. 2009 Jul 1; 49(1):148-54. View in: PubMed

Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. J Infect Dis. 2009 Jun 1; 199(11):1592-8. View in: PubMed

Correlates of perinatal depression in HIV-infected women. AIDS Patient Care STDS. 2009 Feb; 23(2):101-8. View in: PubMed

Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol. 2008 Apr; 41(4):255-63. View in: PubMed

The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat. 2008 Feb; 15(2):120-8. View in: PubMed

Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. J Infect Dis. 2007 May 15; 195(10):1437-42. View in: PubMed

Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis. 2007 Jan 1; 195(1):124-33. View in: PubMed

HIV-1 superinfection is not a common event. J Clin Virol. 2005 Aug; 33(4):328-30. View in: PubMed

Viral and host factors in early hepatitis C virus infection. Hepatology. 2005 Jul; 42(1):86-92. View in: PubMed

Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology. 2004 Sep; 127(3):764-76. View in: PubMed

HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion. 2003 Oct; 43(10):1433-41. View in: PubMed

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med. 2001 Nov 6; 135(9):782-95. View in: PubMed

Surveillance of HIV-1 genetic subtypesand diversity in the US blood supply. Transfusion. 2000 Nov; 40(11):1399-406. View in: PubMed

HIV type 1 tat gene heteroduplex mobility assay as a tool to establish epidemiologic relationships among HIV type 1-infected individuals. AIDS Res Hum Retroviruses. 1999 Sep 1; 15(13):1151-6. View in: PubMed

A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness. J Infect Dis. 1998 Oct; 178(4):1163-6. View in: PubMed

Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol. 1997 Oct 15; 146(8):655-61. View in: PubMed

Influences of age, viral load, and CD4+ count on the rate of progression of HIV-1 infection to AIDS. Transfusion Safety Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1; 15(3):243-4. View in: PubMed

Comparative rates of disease progression among persons infected with the same or different HIV-1 strains. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jun 1; 15(2):145-50. View in: PubMed

Blood donations and viruses. Lancet. 1997 May 3; 349(9061):1327. View in: PubMed

The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996 Aug; 2(8):918-24. View in: PubMed

Hematologic profile and lymphocyte subpopulations in hemoglobin SC disease: comparison with hemoglobin SS and black controls. The Transfusion Safety Study Group. Am J Hematol. 1996 Jul; 52(3):150-4. View in: PubMed

Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis. 1996 Jul; 174(1):26-33. View in: PubMed

Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet. 1995 Nov 4; 346(8984):1224. View in: PubMed

Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis. 1995 Sep; 172(3):648-55. View in: PubMed

Blood transfusions and immunophenotypic alterations of lymphocyte subsets in sickle cell anemia. The Transfusion Safety Study Group. Blood. 1995 Apr 15; 85(8):2091-7. View in: PubMed

Epidemiologic background and long-term course of disease in human immunodeficiency virus type 1-infected blood donors identified before routine laboratory screening. Transfusion Safety Study Group. Transfusion. 1994 Oct; 34(10):858-64. View in: PubMed

Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. Transfusion. 1994 Jun; 34(6):478-83. View in: PubMed

Screening of blood donors for idiopathic CD4+ T-lymphocytopenia. Transfusion. 1994 Mar; 34(3):192-7. View in: PubMed

Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group. Vox Sang. 1994; 67 Suppl 1:24-8. View in: PubMed

Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group. Lancet. 1993 May 29; 341(8857):1373-4. View in: PubMed

Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med. 1993 Feb 11; 328(6):441-2. View in: PubMed

Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders. Pediatrics. 1991 Aug; 88(2):242-9. View in: PubMed

Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990 Nov 15; 113(10):733-9. View in: PubMed

Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group. Vox Sang. 1990; 59(3):129-35. View in: PubMed

Epidemiologic background of blood donors with antibody to human T-cell lymphotropic virus. Transfusion Safety Study Group. Transfusion. 1989 Oct; 29(8):746-8. View in: PubMed

Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. The Transfusion Safety Study/NHLBI Donor Repository. Transfusion. 1989 Sep; 29(7):572-80. View in: PubMed

A case-control study of multiple sclerosis. Neurology. 1989 Jun; 39(6):825-9. View in: PubMed

Phenotypes for group-specific component among patients exposed to human immunodeficiency virus by transfusions. J Infect Dis. 1988 Mar; 157(3):609-10. View in: PubMed

A case-control study of osteosarcoma in young persons. Am J Epidemiol. 1987 Jul; 126(1):118-26. View in: PubMed

Multiple sclerosis among Spanish-surnamed Californians. Neurology. 1978 May; 28(5):434-8. View in: PubMed

Powered bySC CTSI